0001127602-15-004456.txt : 20150205
0001127602-15-004456.hdr.sgml : 20150205
20150205114041
ACCESSION NUMBER: 0001127602-15-004456
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150203
FILED AS OF DATE: 20150205
DATE AS OF CHANGE: 20150205
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PAREXEL INTERNATIONAL CORP
CENTRAL INDEX KEY: 0000799729
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 042776269
STATE OF INCORPORATION: MA
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 195 WEST ST
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 7814879900
MAIL ADDRESS:
STREET 1: 195 WEST ST
CITY: WALTHAM
STATE: MA
ZIP: 02451
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Saarony Gadi
CENTRAL INDEX KEY: 0001552687
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-21244
FILM NUMBER: 15578754
MAIL ADDRESS:
STREET 1: C/O PAREXEL INTERNATIONAL
STREET 2: 195 WEST STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2015-02-03
0000799729
PAREXEL INTERNATIONAL CORP
PRXL
0001552687
Saarony Gadi
C/O PAREXEL INTERNATIONAL
195 WEST STREET
WALTHAM
MA
02451
1
Corp. Sr. VP, CRS
Common Stock
2015-02-03
4
M
0
6200
20.26
A
17300
D
Common Stock
2015-02-03
4
M
0
2325
30.64
A
19625
D
Common Stock
2015-02-03
4
S
0
8525
60.97
D
11100
D
Stock Option (Right to Buy)
20.26
2015-02-03
4
M
0
6200
0
D
2019-09-21
Common Stock
6200
6200
D
Stock Option (Right to Buy)
30.64
2015-02-03
4
M
0
2325
0
D
2020-09-19
Common Stock
2325
4650
D
This transaction was executed in multiple trades through a trade order executed by a broker-dealer at prices ranging from $60.96- $61.04. The price reported in this column reflects the weighted average sale price. For all transactions reported on this Form 4 utilizing a weighted average sale price, the reporting person will provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each price.
Options become exercisable in increments of 25% of the total shares granted commencing on the first anniversary of the date of grant.
/s/ W. Brett Davis, Attorney-in-fact
2015-02-05